1. It has been ~5 years now that they have been marketing and selling the Axiron product. I thought by now they would be much closer to commercialisation and distribution of another (meaningful) product line.
2. Overpaid staff
3. Lack of compliance and shareholder communication. A trading halt should have been requested during pre open following the FDA announcement night before
The FDA announcement in Sep I personally did not thinking it was a big deal. A more detailed warning label is required.....but investors read it as extremely negative - please correct me if my understanding of this is wrong?
Cheers
ACR Price at posting:
$1.07 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)